IKT (Inhibikase Therapeutics) EBITDA Margin % : 0.00% (As of Dec. 2024)

Inhibikase Therapeutics EBITDA Margin % Chart

Inhibikase Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBITDA Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Inhibikase Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Inhibikase Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's EBITDA Margin % falls into.

Inhibikase Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Inhibikase Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Inhibikase Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics  (NAS:IKT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Inhibikase Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibikase Therapeutics Business Description